Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy

Immune checkpoint therapies exhibit impressive efficacy in some patients with melanoma or lung cancer, but the lack of response in most cases presses the question of how general efficacy can be improved. In addressing this question, we generated a preclinical tumor model to study anti-PD-1 resistanc...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Res
Egile Nagusiak: Wang, Xiaohong, Schoenhals, Jonathan E, Li, Ailin, Valdecanas, David R, Ye, Huiping, Zhang, Fenglin, Tang, Chad, Krishnan, Sunil, Allison, James, Sharma, Padmanee, Hwu, Patrick, Komaki, Ritsuko, Overwijk, Willem, Gomez, Daniel R., Chang, Joe Y., Hahn, Stephen M., Cortez, Maria Angelica, Welsh, James W.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2016
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5875182/
https://ncbi.nlm.nih.gov/pubmed/27821490
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-15-3142
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak